2013年8月20日訊 /生物谷BIOON/ --強生（JNJ）8月19日宣布，已完成對Aragon制藥的收購。該公司是一家私營藥品研發(fā)公司，業(yè)務主要集中在激素誘發(fā)的癌癥領域。

此次收購，囊括了Aragon制藥雄激素受體拮抗劑項目，包括前列腺癌主導候選藥物ARN-509，該項目的開發(fā)將由強生旗下楊森（Jassen）研發(fā)單元接管。

ARN-509是第二代雄激素受體信號抑制劑，目前正處于II期臨床開發(fā)，如果獲批，將能夠滿足更廣泛的前列腺癌患者的需求。

此次收購耗資10億美元，包括6.5億預付款項，及3.5億美元的履約款。（生物谷Bioon.com）

英文原文：Johnson & Johnson Completes Acquisition Of Aragon Pharmaceuticals, Inc.

Late-Stage Prostate Cancer Treatment Strengthens Oncology Pipeline

NEW BRUNSWICK, N.J., Aug. 19, 2013 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced it has successfully completed its acquisition of Aragon Pharmaceuticals, Inc., a privately-held pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers.  Development of compounds from Aragon's androgen receptor antagonist program, including its lead androgen receptor signaling inhibitor, ARN-509, will be managed by Janssen Research & Development, LLC.

"The acquisition strengthens our prostate cancer pipeline with a second-generation, potentially best-in-class compound," said Peter F. Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology. "It builds on our existing leadership position with ZYTIGA? (abiraterone acetate), and, if approved, we are hopeful ARN-509 will allow us to meet the needs of an even broader range of prostate cancer patients."

About Johnson & Johnson

Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science—bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 275 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.